Skip to Main content Skip to Navigation
Journal articles

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease

Aurelien Amiot 1, 2 Jean-Charles Grimaud 3 Laurent Peyrin-Biroulet 4 Jérome Filippi 5 Benjamin Pariente 6 Xavier Roblin 7 Anthony Buisson 8 Carmen Stefanescu 9, 10 Caroline Trang-Poisson 11 Romain Altwegg 12 Philippe Marteau 13 Thibaud Vaysse 14 Anne Bourrier 15, 16 Stéphane Nancey 17, 18 David Laharie 19 Matthieu Allez 20 Guillaume Savoye 21, 22, 23 Jacques Moreau 24 Charlotte Gagniere 1, 2 Lucine Vuitton 25 Stephanie Viennot 26 Alexandre Aubourg 27, 28 Anne-Laure Pelletier 29 Guillaume Bouguen 30, 31, 32 Vered Abitbol 33 Yoram Bouhnik 9, 10 Camille Zallot 4 Marc-André Bigard 4 Xavier Hebuterne 34, 5 Maria Nachury 35 Pierre Desreumaux 6, 36, 37 Emilie del Tedesco 38 Gilles Bommelaer 36 Arnaud Boureille 39 Xavier Dray 40, 13 Franck Carbonnel 41 Philippe Seksik 42 Laurent Beaugerie 42 Jacques Cosnes 15, 16 Harry Sokol 42 Cecilia Landman 15, 16 Gilles Boschetti 43 Florian Poullenot 44 Jean-Marc Gornet 45 Clautilde Baudry 46 Stéphane Koch 47 Laurence Picon 48 Gaelle Sickersen 49 Stanislas Chaussade 50 Stephane Nahon 51 Betsy Winkfield 52, 53 Hedia Brixi-Benmansour 53 Rodica Gincul 54 Jean-Christophe Barberis 52 Bruno Bonaz 55 Christophe Michiels 52 Franck Zerbib 19 Marie Beauregard 52 Christophe Locher 56 Sophie Davin-Couve 52 Armelle Poirette 52 Laurence Guillem 52 Monica Stetiu-Mocanu 52 Sylvain Beorchia 52 Jawad Al Qaddi 52
1 LIC - Laboratoire d'Investigation Clinique
2 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)
3 AMU MED - Aix-Marseille Université - Faculté de médecine
4 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
5 CHU Nice - Centre Hospitalier Universitaire de Nice
6 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]
7 CHU de Saint-Etienne - Centre Hospitalier Universitaire de Saint-Etienne
8 CHU Clermont-Ferrand
9 Service de Gastroentérologie [Hôpital Beaujon]
10 UPD7 - Université Paris Diderot - Paris 7
11 Institut des Maladies de l'Appareil Digestif
12 Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi]
13 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
14 Service de neurologie [Le Kremlin Bicêtre]
15 Service de Gastroentérologie et nutrition [CHU Saint-Antoine]
16 DHU i2B - Service de rhumatologie, inflammation-immunopathologie- biothérapie [CHU Saint-Antoine]
17 HCL - Hospices Civils de Lyon
18 UCBL - Université Claude Bernard Lyon 1
19 Service d'Hépato-Gastro-Entérologie
20 Hôpital Saint-Louis
21 ADEN - Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau
22 UNIROUEN - Université de Rouen Normandie
23 IRIB - Institute for Research and Innovation in Biomedicine
24 CHU Toulouse [Toulouse]
25 CHRU Besançon - Centre Hospitalier Régional Universitaire [Besançon]
26 Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen]
27 GICC UMR 7292 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017]
28 CHU Trousseau [Tours]
29 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
30 Foie, métabolismes et cancer
31 Hôpital Pontchaillou
32 UNIV-RENNES - Université de Rennes
33 AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
34 UNS - Université Nice Sophia Antipolis (... - 2019)
35 Hôpital Claude Huriez
36 INSERM - Institut National de la Santé et de la Recherche Médicale
37 Université de Lille, Droit et Santé
38 Service d'Hépato-gastroentérologie [CHU Saint-Etienne]
39 Neuropathies du système nerveux entérique et pathologies digestives; implication des cellules gliales entériques
40 ASTRE [Cergy-Pontoise]
ETIS - UMR 8051 - Equipes Traitement de l'Information et Systèmes
41 AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)
42 CHU Saint-Antoine [AP-HP]
43 Service d'Hépatologie et de Gastroentérologie [Lyon]
44 Hôpital Haut-Lévêque [CHU Bordeaux]
45 AP-HP - Hopital Saint-Louis [AP-HP]
46 Service d'Endocrinologie, Diabétologie, Maladies Métaboliques, Hôpital Avicenne
47 Wallenberg Centre for Molecular Medicine (WCMM)
48 Hépato-Gastro-Onco-Entérologie [CHRU de Tours]
49 Service d'hépato-gastro-entérologie [Hôpital Saint-Louis, APHP]
50 Service de Gastro-entérologie et hépatologie [AP-HP Hôpital Cochin]
51 Service d’hépato-gastro-entérologie [CH Le Raincy-Montfermeil]
52 Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group
53 GETAID - Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif
54 Hôpital Edouard Herriot [CHU - HCL]
55 Equipe 8 : Stress et Interactions neuro-digestives
UJF - Université Joseph Fourier - Grenoble 1, CEA - Commissariat à l'énergie atomique et aux énergies alternatives, INSERM - Institut National de la Santé et de la Recherche Médicale : U836, [GIN] Grenoble Institut des Neurosciences
56 Centre Hospitalier de Meaux
Abstract : Background & aims - Phase 3 trials have shown the efficacy of vedolizumab, which binds to integrin α4β7, in patients with Crohn's disease (CD) or ulcerative colitis (UC). We investigated the effectiveness and safety of vedolizumab in patients who failed anti-tumor necrosis factor therapy. Methods - From June through December 2014, there were 173 patients with CD and 121 patients with UC who were included in a multicenter nominative compassionate early access program granted by French regulatory agencies. This program provided patients with access to vedolizumab before it was authorized for marketing. Vedolizumab (300 mg) was administered intravenously at weeks 0, 2, and 6, and then every 8 weeks. Disease activity was assessed using the Harvey-Bradshaw Index for CD and the partial Mayo Clinic score for UC. We report results obtained after the 14-week induction phase. Results - Among the 294 patients treated with vedolizumab (mean age, 39.5 ± 14.0 y; mean disease duration, 10.8 ± 7.6 y; concomitant steroids, 44% of cases), 276 completed the induction period, however, 18 discontinued vedolizumab because of a lack of response (n = 14), infusion-related reaction (n = 2), or infections (n = 2). At week 14, 31% of patients with CD were in steroid-free clinical remission and 51% had a response; among patients with UC, 36% were in steroid-free clinical remission and 50% had a response. No deaths were reported. Severe adverse events occurred in 24 patients (8.2%), including 15 (5.1%) that led to vedolizumab discontinuation (1 case of pulmonary tuberculosis and 1 rectal adenocarcinoma). Conclusions - In a cohort of patients with CD or UC who failed previous anti-tumor necrosis factor therapy, approximately one third of patients achieved steroid-free clinical remission after 14 weeks of induction therapy with vedolizumab. This agent had an acceptable safety profile in these patients.
Keywords : IBD drug inhibitor cell adhesion
Document type :
Journal articles
Complete list of metadatas
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01278611
Contributor : Nelly Brenner <>
Submitted on : Wednesday, February 24, 2016 - 3:33:37 PM
Last modification on : Wednesday, February 24, 2021 - 9:23:56 AM

Links full text

openaccess

Identifiers

Collections

UNIV-RENNES1 | CNRS | UNIV-CERGY | HCL | HEH | UNIV-NANTES | UNIV-AMU | UNIV-LORRAINE | NUMECAN | NUMECAN-EXPRES | BIOSIT | ETIS-ASTRE | UR1-UFR-SVE | UNICE | COMUE-NORMANDIE | UNIV-COTEDAZUR | UNIV-TOURS | UNIV-RENNES | NGERE-UL | UNICAEN | UNIV-PARIS7 | USPC | UPEC-UPEM | UNIROUEN | UPEC | ADEN | CEA | UNIV-LYON1 | UNIV-MONTPELLIER | UDL | UNIV-PARIS | EC2M3 | BMS-UL | CY-TECH-SM | ETIS | SORBONNE-UNIVERSITE | SU-TI | UNIV-PARIS5

Citation

Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jérome Filippi, Benjamin Pariente, et al.. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, WB Saunders, 2016, 14 (11), pp.1593-1601.e2. ⟨10.1016/j.cgh.2016.02.016⟩. ⟨hal-01278611⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

1651